Greenwich LifeSciences (GLSI)
(Delayed Data from NSDQ)
$12.62 USD
-0.52 (-3.96%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $12.42 -0.20 (-1.58%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Income Statements
Fiscal Year end for Greenwich LifeSciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 9 | 8 | 5 | 2 | 3 |
Income After Depreciation & Amortization | -9 | -8 | -5 | -2 | -3 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -9 | -8 | -5 | -2 | -3 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -9 | -8 | -5 | -2 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -9 | -8 | -5 | -2 | -3 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -9 | -8 | -5 | -2 | -3 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -9 | -8 | -5 | -2 | -3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 12.85 | 12.91 | 12.94 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.69 | -0.61 | -0.35 | NA | NA |
Diluted Net EPS (GAAP) | -0.69 | -0.61 | -0.35 | -0.20 | NA |
Fiscal Year end for Greenwich LifeSciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.83 | 2.50 | 1.75 | 2.24 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.83 | -2.50 | -1.75 | -2.24 |
Non-Operating Income | NA | 0.09 | 0.11 | 0.12 | 0.12 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -2.75 | -2.39 | -1.63 | -2.12 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.75 | -2.39 | -1.63 | -2.12 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.75 | -2.39 | -1.63 | -2.12 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 13.08 | 12.85 | 12.85 | 12.85 |
Diluted EPS Before Non-Recurring Items | NA | -0.21 | -0.19 | -0.13 | -0.17 |
Diluted Net EPS (GAAP) | NA | -0.20 | -0.19 | -0.13 | -0.17 |